This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Mar;44(3):688-92.
doi: 10.1128/AAC.44.3.688-692.2000.

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

Affiliations

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

M L Landry et al. Antimicrob Agents Chemother. 2000 Mar.

Abstract

Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell-associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.

PubMed Disclaimer

References

    1. Chou S, Erice A, Jordan M C, Vercellotti G M, Michels K R, Talarico C L, Stanat S C, Biron K K. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis. 1995;171:576–583. - PubMed
    1. Chou T C. The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Rideout D C, Chou T C, editors. Synergism and antagonism in chemotherapy. San Diego, Calif: Academic Press; 1991. pp. 61–102.
    1. Drew W L, Miner R C, Busch D F, Follansbee S E, Gullett J, Mehalko S G, Gordon S M, Owen Jr W F, Matthews T R, Buhles W C, DeArmond B. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis. 1991;163:716–719. - PubMed
    1. Erice A, Chou S, Biron K K, Stanat S C, Balfour H H, Jr, Jordan M C. Progressive disease due to ganciclovir resistant cytomegalovirus in immunocompromised patients. N Engl J Med. 1989;320:289–293. - PubMed
    1. Erice A, Gil-Roda C, Perez J-L, Balfour Jr H H, Sannerud K J, Hanson M N, Boivin G, Chou S. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis. 1997;175:1087–1092. - PubMed

Publication types

MeSH terms

Full text links
Atypon full text link Atypon Free PMC article
Cite

AltStyle によって変換されたページ (->オリジナル) /